Compare Stocks: MDXG, VRDN, RARE, and CDNA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDNA CareDx	$50.88 +2.0%	$40.72	$13.12 ▼ $53.67	$2.63B	2.43	1.09 million shs	1.31 million shs
MDXG MiMedx Group	$4.57 +3.2%	$4.26	$3.03 ▼ $7.97	$666.12M	1.43	971,087 shs	624,972 shs
RARE Ultragenyx Pharmaceutical	$15.30 +3.0%	$27.76	$13.81 ▼ $39.89	$1.51B	0.31	3.99 million shs	11.48 million shs
VRDN Viridian Therapeutics	$22.92 -0.2%	$21.11	$13.18 ▼ $34.29	$2.60B	0.97	1.37 million shs	759,914 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDNA CareDx	0.00%	+2.19%	+13.55%	+128.67%	+299.69%
MDXG MiMedx Group	0.00%	+1.56%	+9.33%	+22.19%	-35.63%
RARE Ultragenyx Pharmaceutical	0.00%	-40.26%	-40.74%	-30.17%	-51.51%
VRDN Viridian Therapeutics	0.00%	-0.69%	+1.82%	+45.25%	+17.72%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDNA CareDx	$50.88 +2.0%	$40.72	$13.12 ▼ $53.67	$2.63B	2.43	1.09 million shs	1.31 million shs
MDXG MiMedx Group	$4.57 +3.2%	$4.26	$3.03 ▼ $7.97	$666.12M	1.43	971,087 shs	624,972 shs
RARE Ultragenyx Pharmaceutical	$15.30 +3.0%	$27.76	$13.81 ▼ $39.89	$1.51B	0.31	3.99 million shs	11.48 million shs
VRDN Viridian Therapeutics	$22.92 -0.2%	$21.11	$13.18 ▼ $34.29	$2.60B	0.97	1.37 million shs	759,914 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDNA CareDx	0.00%	+2.19%	+13.55%	+128.67%	+299.69%
MDXG MiMedx Group	0.00%	+1.56%	+9.33%	+22.19%	-35.63%
RARE Ultragenyx Pharmaceutical	0.00%	-40.26%	-40.74%	-30.17%	-51.51%
VRDN Viridian Therapeutics	0.00%	-0.69%	+1.82%	+45.25%	+17.72%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CDNA CareDx	2.63	Moderate Buy	$51.20	0.63% Upside
MDXG MiMedx Group	2.71	Moderate Buy	$8.57	87.56% Upside
RARE Ultragenyx Pharmaceutical	2.52	Moderate Buy	$36.63	139.42% Upside
VRDN Viridian Therapeutics	2.85	Moderate Buy	$38.54	68.14% Upside

Current Analyst Ratings Breakdown

Latest MDXG, VRDN, RARE, and CDNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/4/2026	RARE Ultragenyx Pharmaceutical	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$28.00 ➝ $19.00
9/4/2026	RARE Ultragenyx Pharmaceutical	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$43.00 ➝ $32.00
9/3/2026	RARE Ultragenyx Pharmaceutical	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
9/3/2026	RARE Ultragenyx Pharmaceutical	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$77.00 ➝ $28.00
9/3/2026	RARE Ultragenyx Pharmaceutical	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$58.00 ➝ $28.00
9/3/2026	RARE Ultragenyx Pharmaceutical	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$49.00 ➝ $18.00
9/3/2026	RARE Ultragenyx Pharmaceutical	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
9/3/2026	RARE Ultragenyx Pharmaceutical	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$30.00 ➝ $23.00
9/3/2026	RARE Ultragenyx Pharmaceutical	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$83.00 ➝ $37.00
9/3/2026	RARE Ultragenyx Pharmaceutical	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
9/2/2026	CDNA CareDx	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$65.00

(Data available from 9/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CDNA CareDx	$379.80M	6.93	$0.01 per share	7,811.59	$8.23 per share	6.18
MDXG MiMedx Group	$418.63M	1.59	$0.55 per share	8.25	$1.48 per share	3.09
RARE Ultragenyx Pharmaceutical	$673M	2.24	N/A	N/A	($2.95) per share	-5.19
VRDN Viridian Therapeutics	$70.85M	36.65	N/A	N/A	$4.98 per share	4.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CDNA CareDx	-$21.35M	$2.07	24.58	80.76	N/A	24.23%	2.87%	2.17%	11/3/2026 (Estimated)
MDXG MiMedx Group	$48.58M	$0.04	114.28	26.88	N/A	1.76%	12.09%	9.22%	11/4/2026 (Estimated)
RARE Ultragenyx Pharmaceutical	-$575M	-$5.84	N/A	N/A	N/A	-81.79%	-1,024.42%	-44.40%	11/3/2026 (Estimated)
VRDN Viridian Therapeutics	-$342.60M	-$3.37	N/A	N/A	N/A	-505.86%	-72.97%	-42.80%	11/4/2026 (Estimated)

Latest MDXG, VRDN, RARE, and CDNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	VRDN Viridian Therapeutics	-$1.03	-$1.05	-$0.02	-$1.05	$0.06 million	$0.28 million
8/4/2026	Q2 2026	RARE Ultragenyx Pharmaceutical	-$1.22	-$0.90	+$0.32	-$0.90	$183.08 million	$214.00 million
7/30/2026	Q2 2026	CDNA CareDx	$0.2321	$0.37	+$0.1379	$2.07	$114.05 million	$131.95 million
7/29/2026	Q2 2026 & M&A announcement	MDXG MiMedx Group	-$0.0495	-$0.05	-$0.0005	-$0.10	$63.46 million	$64.36 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CDNA CareDx	N/A	N/A	N/A	N/A	N/A
MDXG MiMedx Group	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A
VRDN Viridian Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CDNA CareDx	N/A	4.58	4.51
MDXG MiMedx Group	0.07	5.33	4.79
RARE Ultragenyx Pharmaceutical	N/A	1.73	1.56
VRDN Viridian Therapeutics	0.43	16.95	16.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CDNA CareDx	N/A
MDXG MiMedx Group	79.15%
RARE Ultragenyx Pharmaceutical	97.67%
VRDN Viridian Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
CDNA CareDx	2.40%
MDXG MiMedx Group	2.50%
RARE Ultragenyx Pharmaceutical	5.20%
VRDN Viridian Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CDNA CareDx	740	51.73 million	50.49 million	Optionable
MDXG MiMedx Group	870	145.76 million	142.12 million	Optionable
RARE Ultragenyx Pharmaceutical	1,371	98.59 million	93.46 million	Optionable
VRDN Viridian Therapeutics	50	113.29 million	110.57 million	Optionable

MDXG, VRDN, RARE, and CDNA Headlines

Recent News About These Companies

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Recommendation of "Moderate Buy" from Analysts

September 5 at 6:43 AM | marketbeat.com

268,060 Shares in Viridian Therapeutics, Inc. $VRDN Acquired by Bank of New York Mellon Corp

September 5 at 3:29 AM | marketbeat.com

Wellington Management Group LLP Increases Stock Position in Viridian Therapeutics, Inc. $VRDN

September 4 at 4:40 AM | marketbeat.com

Velan Capital Investment Management LP Has $184,000 Stock Holdings in Viridian Therapeutics, Inc. $VRDN

September 3 at 5:51 AM | marketbeat.com

Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

September 2, 2026 | finance.yahoo.com

The Manufacturers Life Insurance Company Takes $3.31 Million Position in Viridian Therapeutics, Inc. $VRDN

September 2, 2026 | marketbeat.com

Yiheng Capital Management L.P. Has $7.36 Million Holdings in Viridian Therapeutics, Inc. $VRDN

August 31, 2026 | marketbeat.com

Algert Global LLC Sells 81,762 Shares of Viridian Therapeutics, Inc. $VRDN

August 27, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Viridian Therapeutics (VRDN)

August 26, 2026 | theglobeandmail.com

Elmind Capital LP Purchases Shares of 984,931 Viridian Therapeutics, Inc. $VRDN

August 26, 2026 | marketbeat.com

Parkman Healthcare Partners LLC Makes New $25.31 Million Investment in Viridian Therapeutics, Inc. $VRDN

August 25, 2026 | marketbeat.com

Deutsche Bank AG Invests $8.87 Million in Viridian Therapeutics, Inc. $VRDN

August 24, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT) and Viridian Therapeutics (VRDN)

August 21, 2026 | theglobeandmail.com

Insider Selling: Viridian Therapeutics (NASDAQ:VRDN) Insider Sells 14,212 Shares

August 21, 2026 | insidertrades.com

260,000 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Blue Owl Capital Holdings LP

August 21, 2026 | marketbeat.com

Viridian Therapeutics (NASDAQ:VRDN) Insider Jennifer Tousignant Sells 14,212 Shares

August 20, 2026 | marketbeat.com

Handelsbanken Fonder AB Invests $834,000 in Viridian Therapeutics, Inc. $VRDN

August 20, 2026 | marketbeat.com

GSA Capital Partners LLP Invests $903,000 in Viridian Therapeutics, Inc. $VRDN

August 19, 2026 | marketbeat.com

93,414 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Merck & Co. Inc.

August 18, 2026 | marketbeat.com

1,175,906 Shares in Viridian Therapeutics, Inc. $VRDN Bought by Rice Hall James & Associates LLC

August 18, 2026 | marketbeat.com

Bank of America Corp DE Acquires 173,498 Shares of Viridian Therapeutics, Inc. $VRDN

August 18, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXG, VRDN, RARE, and CDNA Company Descriptions

CareDx NASDAQ:CDNA

$50.88 +1.02 (+2.05%)

As of 09/4/2026 04:00 PM Eastern

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

MiMedx Group NASDAQ:MDXG

$4.57 +0.14 (+3.16%)

As of 09/4/2026 04:00 PM Eastern

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

Ultragenyx Pharmaceutical NASDAQ:RARE

$15.30 +0.45 (+3.03%)

As of 09/4/2026 04:00 PM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Viridian Therapeutics NASDAQ:VRDN

$22.92 -0.04 (-0.17%)

As of 09/4/2026 04:00 PM Eastern

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MDXG, VRDN, RARE, and CDNA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MDXG, VRDN, RARE, and CDNA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MDXG, VRDN, RARE, and CDNA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXG, VRDN, RARE, and CDNA Company Descriptions

CareDx NASDAQ:CDNA

MiMedx Group NASDAQ:MDXG

Ultragenyx Pharmaceutical NASDAQ:RARE

Viridian Therapeutics NASDAQ:VRDN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MDXG, VRDN, RARE, and CDNA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MDXG, VRDN, RARE, and CDNA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MDXG, VRDN, RARE, and CDNA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXG, VRDN, RARE, and CDNA Company Descriptions

CareDx NASDAQ:CDNA

MiMedx Group NASDAQ:MDXG

Ultragenyx Pharmaceutical NASDAQ:RARE

Viridian Therapeutics NASDAQ:VRDN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools